Jonathan David Schwartz
Known title: See RemarksCIK: 0001726398
Associated companies
Transaction History
| RCKT | ▼ Sell | Open Market | 2,545 | $8K | 11/18/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 80,000 | $0 | 9/8/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 805 | $2K | 8/19/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,680 | $5K | 8/18/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 11,161 | $34K | 8/14/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 801 | $5K | 5/20/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,582 | $10K | 5/16/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 6,532 | $69K | 2/25/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 80,318 | $0 | 2/11/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,097 | $40K | 11/21/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 2,710 | $50K | 8/16/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 2,754 | $64K | 5/17/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,557 | $68K | 2/17/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 10,562 | $168K | 3/30/2022 | View on chart |
| RCKT | ▼ Sell | Open Market | 34,438 | $570K | 3/30/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.